GSK's mepolizumab gets June 11 FDA panel

FDA's Pulmonary-Allergy Drugs Advisory Committee will meet on June 11 to discuss a BLA from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) for mepolizumab as maintenance therapy for patients with severe eosi...